$1,080,000 of ABBVIE INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 2780, Medication Affordability and Patent Integrity Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property H.R. 830, HELP Copays Act S.1375, HELP Copays Act H.R. 5378, Lower Costs, More Transparency Act S. 1339, Pharmacy Benefit Manager Reform Act Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Issues related to the 340B program H.R. 8816, American Medical Innovation and Investment Act of 2024 Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program and smoothing out-of-pocket costs for patients Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues H.R. 2673, American Innovation and R&D Competitiveness Act of 2023 H.R. 8504, Supply Chain Security and Growth Act of 2024 S. 866, American Innovation and Jobs Act Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program Issues related to antitrust and competition policy"
You can find more data on corporate lobbying on Quiver Quantitative.
ABBV Congressional Stock Trading
Members of Congress have traded $ABBV stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:
- REPRESENTATIVE VIRGINIA FOXX purchased up to $15,000 on 12/06.
- REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $15,000 on 11/20.
- REPRESENTATIVE JOHN JAMES sold up to $15,000 on 09/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
ABBV Insider Trading Activity
ABBV insiders have traded $ABBV stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:
- RICHARD A GONZALEZ (EXECUTIVE CHAIRMAN OF BOARD) sold 66,500 shares for an estimated $12,403,580
- KEVIN K BUCKBEE (SVP, CONTROLLER) sold 1,800 shares for an estimated $310,032
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ABBV Hedge Fund Activity
We have seen 1,577 institutional investors add shares of ABBV stock to their portfolio, and 1,448 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS added 5,167,456 shares (+50.2%) to their portfolio in Q3 2024, for an estimated $1,020,469,210
- INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC removed 4,706,816 shares (-99.6%) from their portfolio in Q4 2024, for an estimated $836,401,203
- INVESCO LTD. added 2,079,684 shares (+36.6%) to their portfolio in Q3 2024, for an estimated $410,695,996
- CAPITAL INTERNATIONAL INVESTORS removed 1,814,340 shares (-4.7%) from their portfolio in Q3 2024, for an estimated $358,295,863
- MORGAN STANLEY added 1,473,173 shares (+4.0%) to their portfolio in Q3 2024, for an estimated $290,922,204
- JPMORGAN CHASE & CO removed 1,445,814 shares (-2.7%) from their portfolio in Q3 2024, for an estimated $285,519,348
- APG ASSET MANAGEMENT N.V. removed 1,414,300 shares (-80.8%) from their portfolio in Q3 2024, for an estimated $279,295,964
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
